Efficacy of Curcumin on Treating Cancer Anorexia-Cachexia Syndrome in Locally or Advanced Head and Neck Cancer: A Double-Blind, Placebo-Controlled Randomised Phase IIa Trial (CurChexia)

Table 2

Primary outcomes: muscle mass, body fat mass, and basal metabolic rate among the curcumin and placebo group patients, as an average change and percentage of an average change.

Group

Muscle mass, kg (mean ± SD)

Body fat mass, kg (mean ± SD)

Basal metabolic rate, kcal (mean ± SD)

Week 0

Week 8

Mean change (95% CI)

% Change (95% CI)

Week 0

Week 8

Mean change (95% CI)

% Change (95% CI)

Week 0

Week 8

Mean Change (95% CI)

% Change (95% CI)

Curcumin

24.04 ± 3.08

24.5 ± 2.72

0.46 (−0.2, 1.12)

2.16 (−0.75, 5.07)

8.64 ± 3.63

8.25 ± 3.47

−0.39 (−1.16, 0.38)

−0.51 (−21.89, 20.86)

1309.3 ± 89.92

1315.1 ± 77.9

5.8 (−23.49, 35.09)

0.54 (−1.6, 2.67)

Placebo

24.31 ± 5.56

23.26 ± 4.85

−1.05 (−2.34, 0.24)

−3.82 (−8.2, 0.57)

10.7 ± 2.75

9.72 ± 2.88

−0.98 (−2.08, 0.12)

−8.97 (−19.43, 1.49)

1339.8 ± 200.36

1317.6 ± 198.44

−22.2 (−56.59, 12.19)

−1.61 (−4.05, 0.84)

values

0.03

0.019

0.334

0.432

0.178

0.153